Form 4: Intuitive Surgical Executive Robert DeSantis Executes Stock Options and Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
EVP & Chief Strategy & Corp Op of Intuitive Surgical, Robert DeSantis, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Robert DeSantis, EVP & Chief Strategy & Corp Op of Intuitive Surgical, executed stock options and sold shares of common stock on June 10, 2024.
- The transactions were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which expires on December 9, 2024.
- DeSantis exercised options to acquire 120 shares at $229.39 and 119 shares at $304.67.
- He then sold 120 shares at $416.6 and 119 shares at $416.6.
- Following these transactions, DeSantis directly owns 5,506 shares of common stock.
- He also holds options to purchase 3,831 shares at $229.39 and 3,831 shares at $304.67.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's performance.
Positives
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating that the sales were planned and not based on insider information.
Future Outlook
The reporting person will continue to execute transactions under the 10b5-1 trading plan until its expiration on December 9, 2024.
Industry Context
Executive stock transactions are common in publicly traded companies and are often scrutinized by investors to gauge management's confidence in the company's future prospects. A 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about insider trading.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are standard across the medical device industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize similar compensation structures for their executives.
- The vesting schedules and exercise prices of the options are within typical ranges for executive compensation packages in comparable companies.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares involved.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/10/2023 | Date from which option vesting begins for Non-Qualified Stock Option at $229.39. |
| 08/10/2023 | Date from which option vesting begins for Non-Qualified Stock Option at $304.67. |
| 06/10/2024 | Date of the stock option exercise and sale transactions. |
| 06/11/2024 | Date of the Form 4 filing. |
| 12/09/2024 | Expiration date of the 10b5-1 trading plan. |
| 02/27/2030 | Expiration date of Non-Qualified Stock Option (right to buy) at $229.39. |
| 08/09/2030 | Expiration date of Non-Qualified Stock Option (right to buy) at $304.67. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.